Commentary: Methodologies to Avoid the Enrollment of Ineligible Patients in Clinical Trials
J Clin Psychiatry 2012;73(11):1426-1427
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
The author comments on the need for improving clinical trial methodology to reduce failure of clinical trials with psychotropic agents. The commentary looks at companion articles that illustrate the problem, the first of which describes a failed study of adjunctive ziprasidone combined with lithium or divalproex compared to lithium or divalproex monotherapy, and the second addresses the influence of protocol-specific eligibility criteria on signal detection in the failed study.